Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03180697 : The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
Phase
AgesMin: 18 Years Max: 80 Years
Eligibility
Inclusion Criteria:

1. malignant glioma patients at least 4 weeks after surgery;

2. after radiotherapy or chemotherapy after the recurrence, stop to put,

3. the age of patients = 18 years old;

4. bone marrow, liver and kidney function is good;

5. not using steroid hormones or disabled for more than 5 days;

6. patients are generally in good condition, expected survival is greater than 8 weeks,
Karnofsky test is greater than 60.

Exclusion Criteria:

1. patients with refractory hypertension, active vascular disease, bleeding, intestinal
perforation and other medical history;

2. frail and difficult to tolerate treatment;

3. HIV positive;

4. pregnant or lactating.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03180697      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740